Jpmorgan Chase & CO Zentalis Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 489,199 shares of ZNTL stock, worth $851,206. This represents 0.0% of its overall portfolio holdings.

Number of Shares
489,199
Previous 495,810 1.33%
Holding current value
$851,206
Previous $2.03 Million 11.45%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$2.9 - $4.57 $19,171 - $30,212
-6,611 Reduced 1.33%
489,199 $1.8 Million
Q3 2024

Nov 08, 2024
SELL
$2.9 - $4.57 $19,171 - $30,212
-6,611 Reduced 1.33%
489,199 $1.8 Million
Q2 2024

Dec 26, 2024
BUY
$4.09 - $16.13 $27,038 - $106,635
6,611 Added 1.35%
495,810 $2.03 Million
Q2 2024

Aug 12, 2024
BUY
$4.09 - $16.13 $1.79 Million - $7.05 Million
437,189 Added 745.79%
495,810 $2.03 Million
Q1 2024

Dec 26, 2024
SELL
$10.83 - $16.49 $4.66 Million - $7.1 Million
-430,578 Reduced 88.02%
58,621 $923,000
Q1 2024

May 10, 2024
SELL
$10.83 - $16.49 $377,176 - $574,297
-34,827 Reduced 37.27%
58,621 $923,000
Q4 2023

Dec 26, 2024
SELL
$9.84 - $20.13 $3.89 Million - $7.97 Million
-395,751 Reduced 80.9%
93,448 $1.42 Million
Q4 2023

Feb 12, 2024
SELL
$9.84 - $20.13 $83,453 - $170,722
-8,481 Reduced 8.32%
93,448 $1.42 Million
Q3 2023

Nov 14, 2023
SELL
$19.63 - $28.29 $172,037 - $247,933
-8,764 Reduced 7.92%
101,929 $2.04 Million
Q2 2023

Aug 11, 2023
BUY
$17.41 - $30.05 $872,101 - $1.51 Million
50,092 Added 82.66%
110,693 $3.12 Million
Q1 2023

May 18, 2023
BUY
$16.14 - $24.94 $927,840 - $1.43 Million
57,487 Added 1846.08%
60,601 $1.04 Million
Q1 2023

May 11, 2023
SELL
$16.14 - $24.94 $705,673 - $1.09 Million
-43,722 Reduced 93.35%
3,114 $53,000
Q4 2022

Feb 13, 2023
BUY
$18.07 - $25.6 $82,146 - $116,377
4,546 Added 10.75%
46,836 $943,000
Q3 2022

Nov 14, 2022
SELL
$20.23 - $31.73 $291,514 - $457,229
-14,410 Reduced 25.41%
42,290 $916,000
Q2 2022

Aug 11, 2022
SELL
$17.91 - $52.25 $875,422 - $2.55 Million
-48,879 Reduced 46.3%
56,700 $1.59 Million
Q1 2022

May 11, 2022
BUY
$41.58 - $80.89 $3.25 Million - $6.32 Million
78,102 Added 284.25%
105,579 $4.87 Million
Q4 2021

Feb 10, 2022
BUY
$66.92 - $84.79 $161,946 - $205,191
2,420 Added 9.66%
27,477 $2.31 Million
Q3 2021

Nov 12, 2021
BUY
$46.83 - $73.5 $1.17 Million - $1.84 Million
25,057 New
25,057 $1.67 Million

Others Institutions Holding ZNTL

# of Institutions
139
Shares Held
67.9M
Call Options Held
48.5K
Put Options Held
89.6K
View Full List

About Zentalis Pharmaceuticals, Inc.

ZNTL Quotes by TradingView
  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $99.2M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email